Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 2/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19971937 | 1.00 | MEN1 (0.48) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL8602068 | 0.92 | TDP1 (0.48) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL17900929 | 0.88 | TDP1 (0.41) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL21982015 | 0.88 | MEN1 (0.52) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL19986282 | 0.88 | MEN1 (0.52) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL21982014 | 0.88 | MEN1 (0.52) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL19971934 | 0.87 | MEN1 (0.53) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL30340151 | 0.86 | MEN1 (0.51) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL22388208 | 0.86 | TDP1 (0.48) | MEN1KMT2AGAATDP1MAPT | |
| SCHEMBL22370726 | 0.86 | TDP1 (0.48) | MEN1KMT2AGAATDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858389-B2 | Solution phase method for preparing etelcalcetide | AMGEN INC. (US) | 2020-12-08 | — | — | US | disclosed |
| EP-3274360-B1 | SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE | AMGEN INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20180079777-A1 | SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE | AMGEN INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858389-B2 | Solution phase method for preparing etelcalcetide | PTH1R, CALCR, SOST | MEN1 697/4885KMT2A 4698/4885GAA 2503/4885 |
| US-20180079777-A1 | SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE | PTH1R, CALCR, SOST | MEN1 697/4885KMT2A 4698/4885GAA 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.